

Ref: FOI/GS/ID 6002

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

19 May 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis.

You asked:

Could you please provide us with the numbers of patients in relation to the questions mentioned below, for a period of last 12 months:

- 1. In your trust how many patients have a diagnosis of Multiple Sclerosis (MS), regardless of whether they are currently on treatment?*
- 2. Of these MS patients, how many have been diagnosed with relapsing (RRMS), primary progressive (PPMS) or secondary progressive (SPMS) MS; If you do not code your MS patients in this way, do you have plans to do this?*

RRMS

PPMS

SPMS

Not known

- 3. How many patients with Multiple Sclerosis have been treated with disease modifying drugs in the past 6 months? Please include all patients whose treatment is ongoing, even those with infrequent dosing schedules (e.g. Lemtrada, Mavenclad, Ocrevus). Please provide the total number of patients by treatment for the following disease modifying drugs:*

Aubagio (teriflunomide)

Avonex (interferon beta-1a)

Betaferon (interferon beta-1b)

Brabio (glatiramer acetate)

Copaxone (glatiramer acetate)

Extavia (beta interferon-1b)

Gilenya (fingolimod)

Lemtrada (alemtuzumab)

Mavenclad (cladribine)

Mayzent (siponimod)

Ocrevus (ocrelizumab)
Plegridy (peginterferon beta-1a)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Vumerity (diroximel fumarate)
Zinbryta (daclizumab)
Ampyra (fampyra)
Ozanimod

4. Of the patients who are receiving Ocrevus (Ocrelizumab) , how many are primary progressive (PPMS)? If unknown, please state unknown.

5. How many patients have been treated with these drugs in the past 6 months, regardless of diagnosis?

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Brabio (glatiramer acetate)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Mavenclad (cladribine)
Mayzent (siponimod)
Ocrevus (ocrelizumab)
Plegridy (peginterferon beta-1a)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Vumerity (diroximel fumarate)
Zinbryta (daclizumab)
Ampyra (fampyra)
Ozanimod

Trust response:

1. The Trust has a caseload of slightly under 400 patient with MS for the Tunbridge Wells / Sevenoaks/ Edenbridge/ Tonbridge / some of the Cranbrook and East Sussex areas.

2. In the last 12 months we have had:

Tunbridge Wells Hospital - 16 newly diagnosed MS patients.

14 diagnosed with RRMS and 2 patients with CIS.

No PPMS diagnosed.

Secondary progressive referred back in SPMS who were lost to follow up or a transfer from somewhere else.

Maidstone Hospital - New Patients = 20 for Maidstone

RRMS = 12

SPMS = 5

PPMS = 2

CIS = 1

Treatments for RRMS:

Copaxone = 3

Plegridy = 1

Avonex = 1

Gilenya = 2

Tecfidera = 5

3. We have about 319 patients on average of patients on DMTs, this is across both sites. In order to give further detail the Trust would need to look at each individual patient record. The Trust has estimated that it will cost more than the appropriate limit to consider this part of your request. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with this part of your request and we will not be processing this part of your request further.

4. Not known

5.

Aubagio (teriflunomide)	20
Avonex (interferon beta-1a)	28
Betaferon (interferon beta-1b)	6
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	44
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	19
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Plegridy (peginterferon beta-1a)	12
Rebif (beta interferon-1a)	12
Tecfidera (dimethyl fumarate)	78
Tysabri (natalizumab)	0
Vumerity (diroximel fumarate)	0
Zinbryta (daclizumab)	0
Ampyra (fampyra)	0
Ozanimod	0